Australia markets open in 4 hours 43 minutes

Anavex Life Sciences Corp. (AVXL)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
19.45+0.46 (+2.42%)
At close: 1:00PM EST
19.85 +0.40 (+2.06%)
After hours: 04:54PM EST
Full screen
Trade prices are not sourced from all markets
Previous close18.99
Open18.20
Bid19.55 x 1200
Ask19.58 x 800
Day's range18.10 - 19.95
52-week range4.51 - 31.50
Volume793,636
Avg. volume795,192
Market cap1.479B
Beta (5Y monthly)0.67
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • GlobeNewswire

    Anavex Life Sciences Provides Business Update and Reports Fiscal 2021 Year End Financial Results

    Webcast and Conference Call Today at 4:30 p.m. Eastern TimeNEW YORK, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today reported financial results for its fiscal year ende

  • GlobeNewswire

    Anavex Life Sciences to Announce Fiscal 2021 Year End Financial Results on Wednesday, November 24, 2021

    Webcast and Conference Call To be Held Wednesday November 24, 2021, 4:30 pm EDTNEW YORK, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that it will issue fi

  • GlobeNewswire

    Anavex Life Sciences Announces Participation at Upcoming Lausanne VIII Workshop Panel - Building Global Momentum for Interventions in Alzheimer’s Disease

    Lausanne VIII Workshop for Leaders and Innovators in Alzheimer’s will be held, November 15, 2021 - November 18, 2021NEW YORK, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases,